Načítá se...
Ribonucleotide reductase represents a novel therapeutic target in primary effusion lymphoma
Primary effusion lymphoma (PEL) is a highly aggressive B-cell malignancy that is closely associated with one of oncogenic viruses infection, Kaposi's sarcoma-associated herpesvirus (KSHV). PEL prognosis is poor and patients barely survive more than 6 months even following active chemotherapy in...
Uloženo v:
| Vydáno v: | Oncogene |
|---|---|
| Hlavní autoři: | , , , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
2017
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5578886/ https://ncbi.nlm.nih.gov/pubmed/28459467 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/onc.2017.122 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|